FBR & Co reissued their outperform rating on shares of Prima BioMed Ltd. (NASDAQ:PBMD) in a report issued on Friday. The firm currently has a $6.00 price target on the stock.
Immutep Ltd. buy Quitte
Start price
21.07.16
/
50%
€0.15
Target price
23.01.17
€0.20
Performance (%)
-13.33%
End price
23.01.17
€0.13
Summary
This prediction ended on 23.01.17 with a price of €0.13. The prediction for Immutep Ltd. disappointed with a performance of -13.33%. Quitte has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Immutep Ltd. | 9.195% | 9.195% | -0.524% | -36.348% |
iShares Core DAX® | 1.280% | 1.320% | 13.605% | 15.782% |
iShares Nasdaq 100 | -2.457% | -5.192% | 25.941% | 38.434% |
iShares Nikkei 225® | -2.006% | -1.389% | 8.973% | 6.570% |
iShares S&P 500 | -0.662% | -1.884% | 23.684% | 39.611% |
Comments by Quitte for this prediction
In the thread Immutep Ltd. diskutieren
wer wagt ....
(Laufzeit überschritten)